Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging

Journal of Molecular Medicine

Volumn 90, Issue 1, 2012, Pages 55-66

  Eckl, Judith ^a   Buchner, Alexander ^b,c   Prinz, Petra U ^a   Riesenberg, Rainer ^b   Siegert, Sabine I ^d   Kammerer, Robert ^e   Nelson, Peter J ^c   Noessner, Elfriede ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

Immunotherapy; NK cells; Prognosis; Renal cell carcinoma; Transcript signature

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PERFORIN;

ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER STAGING; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; METHODOLOGY; NATURAL KILLER CELL; PREDICTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHEMOKINE CX3CL1; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NEOPLASM STAGING; PERFORIN; PROGNOSIS; RECEPTORS, CHEMOKINE;

EID: 84857372947     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0806-7     Document Type: Article

References (35)

1. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ (2009) Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 56:636-643
2. Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W (2007) TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 8:554-558 (Pubitemid 46805912)
3. Gore ME, Larkin JM (2011) Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 104:399-406
4. Wong MK (2008) The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Curr Oncol Rep 10:259-263
5. Frankenberger B, Noessner E, Schendel DJ (2007) Immune suppression in renal cell carcinoma. Semin Cancer Biol 17:330-343 (Pubitemid 47211966)
6. dull phenotype induction. Blood 109:323-330 (Pubitemid 46053073)
7. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861 (Pubitemid 37328903)
8. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ (2003) NK cells and the tumour microenvironment: implications for NK-cell function and antitumour activity. Trends Immunol 24:603-609 (Pubitemid 37338529)
9. van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH (2005) Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 11:1899-1909 (Pubitemid 40471856)
10. Hersey P, Hobbs A, Edwards A, McCarthy WH, McGovern VJ (1982) Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 42:363-368 (Pubitemid 12207293)
11. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356:1795-1799
12. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ et al (2006) Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12:718-725 (Pubitemid 43259850)
13. Schmid H, Cohen CD, Henger A, Schlondorff D, Kretzler M (2004) Gene expression analysis in renal biopsies. Nephrol Dial Transplant 19:1347-1351 (Pubitemid 38786719)
14. Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M (2003) Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J Immunol Methods 280:1-11 (Pubitemid 37289211)
15. Taylor JM, Ankerst DP, Andridge RR (2008) Validation of biomarkerbased risk prediction models. Clin Cancer Res 14:5977-5983
16. Zou J, Han Y, So SS (2008) Overview of artificial neural networks. Methods Mol Biol 458:15-23
17. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633-640 (Pubitemid 33043908)
18. Walzer T, Jaeger S, Chaix J, Vivier E (2007) Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol 19:365-372 (Pubitemid 46687010)
19. Caligiuri MA (2008) Human natural killer cells. Blood 112:461-469
20. Morris MA, Ley K (2004) Trafficking of natural killer cells. Curr Mol Med 4:431-438 (Pubitemid 38787011)
21. Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, Sica A (2004) Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 14:155-160 (Pubitemid 38586740)
22. Beilke JN, Kuhl NR, Van Kaer L, Gill RG (2005) NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 11:1059-1065 (Pubitemid 41486827)
23. Moffett-King A (2002) Natural killer cells and pregnancy. Nat Rev Immunol 2:656-663 (Pubitemid 37328723)
24. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG (2002) The natural killer cell-friend or foe in autoimmune disease? Scand J Immunol 55:432-441 (Pubitemid 34451228)
25. Ottaviani C, Nasorri F, Bedini C, de Pita O, Girolomoni G, Cavani A (2006) CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 36:118-128 (Pubitemid 43116398)
26. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, Shi FD (2010) Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 207:1907-1921
27. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I et al (2011) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 17:678-689
28. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148-1152 (Pubitemid 30067223)
29. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L (2003) The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 33:2410-2418 (Pubitemid 37138973)
30. Lieberman J, Shankar P, Manjunath N, Andersson J (2001) Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98:1667-1677
31. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F et al (2003) Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to selfantigens in human metastatic melanoma. Cancer Res 63:2535-2545 (Pubitemid 36605194)
32. - human natural killer cells. Blood 102:1569-1577 (Pubitemid 37022543)
33. Umehara H, Bloom E, Okazaki T, Domae N, Imai T (2001) Fractalkine and vascular injury. Trends Immunol 22:602-607
34. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188:1413-1419 (Pubitemid 28489578)
35. Guo J, Chen T,Wang B, Zhang M, An H, Guo Z, Yu Y, Qin Z, Cao X (2003) Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 89:1-7 (Pubitemid 37289511)